Status: Recruiting
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
The goal of this study is to evaluate the safety and effectiveness of EVOLVE104 in participants with advanced urothelial and squamous cell carcinomas who have previously taken standard treatment options, have declined or have been ineligible for treatment with these medications. Participants with advanced or metastatic cancer who meet all eligibility criteria may be eligible to participate in the study.
Participants needed: 160
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: EvolveImmune United, IncUpdated: Jul 2, 2026Locations: 12
Eligibility criteria
Participant must have documented disease progression during or post treatment wi... [+6]
The participant is a candidate for treatment with a targeted agent known to prov... [+12]